NCT05384769Active, not recruiting
Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
Feasibility Study of Lung Cancer Screening Using Cell-Free DNA Liquid Biopsy at Home in High-Risk Current and Former Smokers
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
This clinical trial investigates how practical and doable (feasibility) cell-free deoxyribonucleic acid (DNA) liquid biopsy is in screening high-risk patients for lung cancer. Currently, a low dose computed tomography (CT) scan is used to screen for lung cancer, however, due to various factors, few high-risk patients are screened. Liquid biopsy utilizes technology that can detect small amounts of DNA shed by cancer cells and may be able to spot lung cancer at an earlier stage. If a positive result comes back from the liquid biopsy, a patient may be more willing to get a low dose CT (LDCT) scan, possibly confirming the biopsy's findings and thus leading to more early lung cancer detection.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- First submitted
- 19 Apr 2022
- Start date
- 29 Jul 2022
- Primary completion date
- 28 Jan 2027
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Lung cancer
- NCT number
- NCT05384769
What you commit to
- Study type: Interventional
- Planned participants: 108
- From 29 Jul 2022 to the primary completion date, 28 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Symptoms of lung cancer.
- Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer.
Other
- Chest CT scan or chest positron emission tomography (PET)/CT within 12 months.
- Unable to undergo LDCT at either City of Hope Duarte, Newport Beach, or Lancaster.
Who the study is looking for
- Documented written informed consent of the participant.
- Age 50-80 years.
- Smoking history of \>= 20 pack-years and if quit, quit within 15 years.
- Received referral for counseling for lung cancer screening and would qualify for LDCT.
- Health Insurance that will pay for a LDCT for lung cancer screening at either City of Hope Duarte, Newport Beach (Newport Diagnostic Imaging), or Lancaster (Renaissance Imaging/Antelope Valley Outpatient Imaging Center).
- Willingness to provide blood sample.
- English speaking.
- Consent to undergo lung cancer screening with either liquid biopsy (LB) or LDCT.
Age in the registry: 50 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.